#esmobreast2025

Happy to see the @breastcancerorg.bsky.social highlighting our study presented at the #ESMOBreast2025 🔬

At #ESMOBreast2025, @sixtenharborg.bsky.social
shared a significant analysis from the Nurses’ Health Study showing that weight gain after diagnosis may raise #breastcancer death risk. Study followed 6,800+ women between 1978 - 2018, with follow-up ranging from 4–15 years.
🔗http://bit.ly/ESMO2025

Pretreatment ctDNA Status Is Associated With Distant Recurrent-Free Survival in Early Breast Cancer Baseline ctDNA concentration was shown to be the most significant predictor of distant recurrence-free survival in patients with early breast cancer.

Pretreatment ctDNA Status Is Associated With Distant Recurrent-Free Survival in Early Breast Cancer @ucsfcancer.bsky.social @myesmo.bsky.social #ESMOBreast2025 #oncology
www.onclive.com/view/pretrea...

Zanidatamab/Chemotherapy Yields Responses and Is Safe in HER2-Expressing Metastatic Breast Cancer Zanidatamab/chemotherapy showed early antitumor activity with a manageable safety profile in patients with HER2-expressing metastatic breast cancer.

Zanidatamab/Chemotherapy Yields Responses and Is Safe in HER2-Expressing Metastatic Breast Cancer @erikahamilton9.bsky.social @myesmo.bsky.social #ESMOBreast2025 #bcsm #oncology
www.onclive.com/view/zanidat...

Puxitatug Samrotecan Yields Responses With Manageable Safety in Pretreated HR+/HER2– Advanced Breast Cancer Puxitatug samrotecan demonstrated manageable safety and early efficacy in HR-positive/HER2-negative advanced breast cancer.

Puxitatug Samrotecan Yields Responses With Manageable Safety in Pretreated HR+/HER2– Advanced Breast Cancer @myesmo.bsky.social #esmobreast2025 #oncology

www.onclive.com/view/puxitat...

Powerful advocate presentation by @donjetazeqa.bsky.social for inflammatory breast cancer patients at #esmobreast2025 🩷🩷

ESMO breast IBC session presenters informal meet up

ESMO breast IBC presenters on stage

Thanks @myesmo.bsky.social for including IBC in the #esmobreast2025 line up. Great brainstorming with this group and strong message: guideline concordant care for all IBC, use the @susangkomen.bsky.social IBC tools at diagnosis, don’t de-escalate off protocol! #cansky #oncsky #bcsm